The biotech Mesoblast is starting a compassionate use study of its stem cell product for kids with a severe offshoot of COVID-19.
The cellular drug in this case is remestemcel-L (more below).
While most children fare better than adults in dealing with COVID-19, the rare subset of kids with COVID-19 for this study have more severe disease than the average COVID patient and some die.
Comments are closed.